Physician profile
Melissa Q Lee
NPI 1639140122
$2,285.33
in general payments reported to CMS, 2019-2025
30 companies · $537 in 2025
The $537 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $944 · 2020: $109 · 2021: $37.90 · 2023: $105 · 2024: $553 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,194.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $454.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $211.28 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $205.23 | 2019-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $188.61 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Daiichi Sankyo INC. | $158.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.12 | 2024-2025 | Jardiance |
| Abbott Laboratories | $114.74 | 2023-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $92.95 | 2019 | |
| Pfizer INC. | $84.03 | 2019-2024 | |
| Exact Sciences Corporation | $83.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $80.93 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $79.94 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $67.57 | 2025 | |
| Leo Pharma As | $37.90 | 2021 | |
| Janssen Biotech, INC. | $30.61 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $23.91 | 2025 | Gemtesa |
| Biogen, INC. | $22.44 | 2024 | Skyclarys |
| Phathom Pharmaceuticals, INC. | $21.94 | 2024 | Voquezna |
| Boston Scientific Corporation | $20.72 | 2024 | Bodyguardian |
| Inspire Medical Systems, INC. | $19.27 | 2024 | Inspire |
| Novartis Pharmaceuticals Corporation | $18.60 | 2019 | |
| Intra-Sana Laboratories | $18.45 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Idorsia Pharmaceuticals US INC | $17.96 | 2024 | Quviviq |
| Exeltis, USA INC. | $17.46 | 2019 | |
| Amarin Pharma, INC. | $16.71 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.51 | 2024 | Camzyos |
| Kowa Pharmaceuticals America, INC. | $15.40 | 2019 | |
| Philips North America LLC | $13.39 | 2024 | (Ak6) Vest Therapy |
| Xeris Pharmaceuticals, INC. | $13.38 | 2023 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.